Pipeline Launches And Demographic Trends Will Drive Broad Gene Adoption
AN
AnalystHighTarget
Not Invested
Consensus Narrative from 12 Analysts
Published
09 Aug 25
Updated
21 Aug 25
AnalystHighTarget's Fair Value
US$51.93
82.7% undervalued intrinsic discount21 Aug
US$9.01
1Y
-25.7%7D
2.2%